Intrabody construction and expression. II. A synthetic catalytic Fv fragment

Journal of Molecular Biology

Volumn 291, Issue 5, 1999, Pages 1129-1134

  Ohage, Ettore C ^a   Wirtz, Peter ^a   Barnikow, Jan ^a   Steipe, Boris ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Catalytic antibodies; Immunoglobulin engineering; Intrabodies; Protein engineering; Protein stability

Indexed keywords

DISULFIDE; IMMUNOGLOBULIN;

ARTICLE; CONTROLLED STUDY; CYTOLOGY; CYTOPLASM; ESCHERICHIA COLI; GENE THERAPY; GENETIC ENGINEERING; IMMUNOGLOBULIN VARIABLE REGION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING;

ESCHERICHIA COLI;

EID: 0033520452     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1999.3020     Document Type: Article

References (30)

1. Biocca S., Ruberti F., Tafani M., Pierandrei A. P., Cattaneo A. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. Biotechnology. 13:1995;1110-1115.
2. Bothwell A. L., Paskind M., Reth M., Imanishi K. T., Rajewsky K., Baltimore D. Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a gamma 2a variable region. Cell. 24:1981;625-637.
3. Carter P., Merchant A. M. Engineering antibodies for imaging and therapy. Curr. Opin. Biotechnol. 8:1997;449-454.
4. Cattaneo A., Biocca S. The selection of intracellular antibodies. Trends Biotechnol. 17:1999;115-121.
5. Gargano N., Cattaneo A. Rescue of a neutralizing anti-viral antibody fragment from an intracellular polyclonal repertoire expressed in mammalian cells. FEBS Letters. 414:1997;537-540.
6. Gill S. C., von Hippel P. H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182:1989;319-326.
7. Gittelman M. S., Matthews C. R. Folding and stability of trp aporepressor from Escherichia coli. Biochemistry. 29:1990;7011-7020.
8. Glockshuber R., Schmidt T., Plückthun A. The disulfide bonds in antibody variable domains: effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry. 31:1992;1270-1279.
9. Guo J., Huang W., Scanlan T. S. Kinetic and mechanistic characterization of an efficient hydrolytic antibody: evidence for the formation of an acyl intermediate. J. Am. Chem. Soc. 116:1994;6062-6069.
10. Hudson P. J. Recombinant antibody fragments. Curr. Opin. Biotechnol. 9:1998;395-402.
11. Kabat E. A., Wu T. T., Perry H. M., Gottesman K. S., Foeller C. Distribution Files of the Fifth Edition of Sequences of Proteins of Immunological Interest, http://immuno.bme.nwu.edu/. 1992.
12. Maciejewski J. P., Weichold F. F., Young N. S., Cara A., Zella D., Reitz M. J., Gallo R. C. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Med. 1:1995;667-673.
13. Marasco W. A. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Therapy. 4:1997;11-15.
14. Marasco W. A., Chen S., Richardson J. H., Ramstedt U., Jones S. D. Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Human Gene Therapy. 9:1998;1627-1642.
15. Martineau P., Jones P., Winter G. Expression of an antibody fragment at high levels in the bacterial cytoplasm. J. Mol. Biol. 280:1998;117-127.
16. Ohage E. C., Steipe B. Intrabody construction and expression. I. The critical role of VL domain stability. J. Mol. Biol. 291:1999;1119-1128.
17. Ohage E. C., Graml W., Walter M. M., Steinbacher S., Steipe B. Beta-turn propensities as paradigms for the analysis of structural motifs to engineer protein stability. Protein Sci. 6:1997;233-241.
18. Proba K., Honegger A., Plückthun A. A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J. Mol. Biol. 265:1997;161-172.
19. Proba K., Worn A., Honegger A., Plückthun A. Antibody scFv fragments without disulfide bonds made by molecular evolution. J. Mol. Biol. 275:1998;245-253.
20. Rondon I. J., Marasco W. A. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu. Rev. Microbiol. 51:1997;257-283.
21. Schultz P. G., Lerner R. A. From molecular diversity to catalysis: lessons from the immune system. Science. 269:1995;1835-1842.
22. Skerra A. Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene. 151:1994;131-135.
23. Smithrud D. B., Benkovic S. J. The state of antibody catalysis. Curr. Opin. Biotechnol. 8:1997;459-466.
24. Steipe B., Plückthun A., Huber R. Refined crystal structure of a recombinant immunoglobulin domain and a complementarity-determining region 1-grafted mutant. J. Mol. Biol. 225:1992;739-753.
25. Steipe B., Schiller B., Plückthun A., Steinbacher S. Sequence statistics reliably predict stabilizing mutations in a protein domain. J. Mol. Biol. 240:1994;188-192.
26. Wirtz P., Steipe B. Intrabody construction and expression III: Engineering hyperstable VH domains. Protein Sci. 1999.
27. Wörn A., Plückthun A. An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Letters. 427:1998;357-361.
28. Wu Y., Duan L., Zhu M., Hu B., Kubota S., Bagasra O., Pomerantz R. J. Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition. J. Virol. 70:1996;3290-3297.
29. Wülfing C., Lombardero J., Plückthun A. An Escherichia coli protein consisting of a domain homologous to FK506- binding proteins (FKBP) and a new metal binding motif. J. Biol. Chem. 269:1994;2895-2901.
30. Zhou G. W., Guo J., Huang W., Fletterick R. J., Scanlan T. S. Crystal structure of a catalytic antibody with a serine protease active site. Science. 265:1994;1059-1064.